{"atc_code":"L03AA14","metadata":{"last_updated":"2021-02-10T23:33:41.326658Z","applied_components":{"study-ids-enricher":{"output_fields":["attachment.studies","attachment.max_study_phase"],"input_checksum":"484160db9d3371ae300d38731c443b75a89baa65477154bb07091a47e749a401","last_success":"2021-02-10T23:36:26.635903Z","output_checksum":"f429f64808d84b4b08098bf403595a8de2439affb9624c54bcfd025793addffd","success":true,"name":"study-ids-enricher","input_fields":["attachment.type","active_substance","attachment.content"],"version":28,"finish_time":"2021-02-10T23:36:26.635903Z","status":"NOT_APPLICABLE"},"EmaDataAccessor":{"output_fields":[],"input_checksum":"44136fa355b3678a1146ad16f7e8649e94fb4fc21fe77e8310c060f61caaff8a","last_success":"2021-02-10T23:33:41.326655Z","output_checksum":"44136fa355b3678a1146ad16f7e8649e94fb4fc21fe77e8310c060f61caaff8a","success":true,"name":"EmaDataAccessor","input_fields":[],"version":3,"finish_time":"2021-02-10T23:33:41.326655Z","status":"UP_TO_DATE"},"section_ranges_extraction":{"output_fields":["attachment.labelSections"],"input_checksum":"f336b21f17bdbcfc74c5f49abbcce54162c9017178a5ee9ba10e465e20f90ce9","last_success":"2021-02-10T23:37:10.690959Z","output_checksum":"f429f64808d84b4b08098bf403595a8de2439affb9624c54bcfd025793addffd","success":true,"name":"section_ranges_extraction","input_fields":["attachment.type","attachment.content"],"version":2,"finish_time":"2021-02-10T23:37:10.690959Z","status":"UP_TO_DATE"},"prime_designation_enricher":{"output_fields":["prime_designation"],"input_checksum":"f336b21f17bdbcfc74c5f49abbcce54162c9017178a5ee9ba10e465e20f90ce9","last_success":"2021-02-11T05:31:58.503538Z","output_checksum":"dcf4d2ed94fa29974e643bd4a70cd26ec785f1130958f3e23e8022193699a97a","success":true,"name":"prime_designation_enricher","input_fields":["attachment.type","attachment.content"],"version":3,"finish_time":"2021-02-11T05:31:58.503538Z","status":"UP_TO_DATE"}},"agency":"EMA","product_id":"A8DF7D061E81D103BB4E2CC9B7E0211F","direct_link":"https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex","first_created":"2021-02-10T23:33:41.140326Z"},"revision_number":19,"approval_status":"authorised","active_substance":"lipegfilgrastim","additional_monitoring":false,"inn":"lipegfilgrastim","prime_designation":false,"accelerated_assessment":false,"orphan":false,"product_name":"Lonquex","authorization_holder":"Teva B.V.","generic":false,"product_number":"EMEA/H/C/002556","initial_approval_date":"2013-07-25","attachment":[{"last_updated":"2021-02-10","link":"https://www.ema.europa.eu/documents/product-information/lonquex-epar-product-information_en.pdf","id":"CB6AF80F3C85C7472B465A4591C2F782","type":"productinformation","title":"Lonquex : EPAR - Product Information","first_published":"2013-09-02"}],"conditional_approval":false,"exceptional_circumstances":false,"indication":"<div> \n <div class=\"ecl-field__body\"> \n  <div class=\"ecl-editor first last\">\n   <p>Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).</p>\n  </div> \n </div> \n</div>","therapeutic_area":"Neutropenia","contact_address":"Swensweg 5\n2031GA Haarlem\nThe Netherlands","biosimilar":false}